Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 10, 2012

View Archived Issues

Shionogi reports on first quarter of 2012

Synthetic Biologics to use Intrexon technology for mAb development

Genkyotex product attenuates liver fibrosis in vivo

University of Queensland researcher receives grant for nanoparticle delivery system

Novel computational method pairs known drugs with new uses

Researchers describe vaccine's cross-reactivity against Nipah virus

Abbott designs novel ALK blockers

Research at Actelion yields new S1P1 receptor agonists

Actinium and Philogen partner to develop adhesion-targeted anticancer radiotherapies

Dutch regulatory agency denies approval of Cortiment

New HDAC8/HDAC6 inhibitors patented

Salix and Alfa Wassermann enter agreement for EIR rifaximin formulation

FDA requests new validated test system for immunoglobulin preparation

McGill University presents new antibiotics

Topically delivered nanoparticle-siRNA conjugates suppress gene expression in vivo

Astellas and AstraZeneca gain approval in Japan for COPD therapeutic

Novel beta-secretase inhibitors created at Eisai

Japanese MHLW approves Bactramin/Baktar for additional indication

Humira approved for additional indication in Japan

Acquisition of Amylin Pharmaceuticals complete

AnaMar to conduct phase II studies of new analgesic and anti-inflammatory drug

Clovis Oncology launches CP-4126 combination trial

Galenea and CHDI Foundation extend and expand Huntington's disease collaboration

Nodality and Pfizer enter multiyear strategic collaboration

Sunitinib capsules approved in Japan for treatment of pancreatic neuroendocrine tumors

Japanese authorities grant new approval to ultrasound contrast agent

Flagyl approved for additional indication in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 17, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...